Symmetry Partners LLC Invests $924,000 in Insulet Co. (NASDAQ:PODD)

Symmetry Partners LLC purchased a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,968 shares of the medical instruments supplier's stock, valued at approximately $924,000.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in Insulet during the second quarter valued at $32,000. UMB Bank n.a. raised its stake in shares of Insulet by 81.0% in the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock valued at $37,000 after acquiring an additional 81 shares during the period. CVA Family Office LLC lifted its holdings in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 145 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV boosted its stake in shares of Insulet by 159.2% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier's stock worth $51,000 after purchasing an additional 156 shares during the period.

Insulet Stock Up 1.8 %

Shares of NASDAQ PODD traded up $4.08 during midday trading on Friday, reaching $235.61. 385,298 shares of the company's stock traded hands, compared to its average volume of 429,923. The company has a market cap of $16.52 billion, a price-to-earnings ratio of 42.84, a P/E/G ratio of 4.32 and a beta of 1.22. The stock's 50 day simple moving average is $227.10 and its 200-day simple moving average is $201.20. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36. Insulet Co. has a one year low of $137.68 and a one year high of $243.98.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The company had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm's revenue was up 23.2% compared to the same quarter last year. During the same period last year, the business posted $0.38 EPS. On average, analysts predict that Insulet Co. will post 3.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the subject of several analyst reports. UBS Group raised their price objective on shares of Insulet from $211.00 to $223.00 and gave the stock a "neutral" rating in a research note on Friday, August 9th. Piper Sandler raised their price target on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 17th. Raymond James upped their price objective on Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday, October 14th. BTIG Research lifted their target price on Insulet from $250.00 to $260.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Finally, Citigroup boosted their target price on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research note on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $242.29.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.